Press Releases

Date Title and Summary Additional Formats
Toggle Summary Addition of algenpantucel-L immunotherapy to standard of care (SOC) adjuvant therapy for pancreatic cancer View HTML
Toggle Summary Clinical Data from NewLink Genetics' HyperAcute Prostate Cancer Immunotherapy Published in Journal of Immunotherapy
- Data Continues to Support the use of NewLink's HyperAcute® Immunotherapy to Elicit a Response in Tumor-Specific Antigens Common to both the Immunotherapy and the Patient's Tumor Cells -
View HTML
Toggle Summary CORRECTED: NewLink Genetics Reports Third Quarter 2018 Financial Results and Announces Abstracts to Be Presented at Upcoming Medical Meetings
AMES, Iowa , Nov. 02, 2018 (GLOBE NEWSWIRE) -- In a release issued under the same headline yesterday by NewLink Genetics Corporation (NASDAQ:NLNK), the balance statement included in the press release was incorrect. The corrected release follows: NewLink Genetics Corporation (NASDAQ:NLNK) yesterday
View HTML
Toggle Summary CORRECTION - NewLink Genetics to Present at the Oppenheimer 24th Annual Healthcare Conference
AMES, IA -- (Marketwired) -- 12/05/13 -- In the news release, " NewLink Genetics to Present at the Oppenheimer 24th Annual Healthcare Conference," issued earlier today by NewLink Genetics Corporation (NASDAQ: NLNK), we are advised by the company that the conference date in the first paragraph
View HTML
Toggle Summary Data From an Investigator-Initiated Phase 2 Study of NewLink Genetics' HyperAcute® Melanoma Immunotherapy Published in 2012 ASCO Annual Meeting Abstracts
HyperAcute Melanoma Demonstrates Activity in Stage III and Stage IV Patients
View HTML
Toggle Summary Data from Clinical Studies of NewLink Genetics' Two Distinct IDO Pathway Inhibitors to Be Presented at ASCO 2017
AMES, Iowa , May 17, 2017 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced that abstracts from two clinical studies of its IDO pathway inhibitors, indoximod and navoximod (GDC-0919), used in combination with other agents, are now available on the website of the 2017
View HTML
Toggle Summary Data from Clinical Study of NewLink Genetics' IDO Pathway Inhibitor, Indoximod, to Be Presented at the 22nd European Hematology Association Congress
AMES, Iowa , May 18, 2017 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced that an abstract describing data from a clinical study of its IDO pathway inhibitor, indoximod, in combination with chemotherapeutic agents for patients with newly diagnosed acute myelogenous
View HTML
Toggle Summary Data From NewLink Genetics Phase 2 Trial of Its HyperAcute(R) Pancreas (Algenpantucel-L) Immunotherapy to be Presented at the 2012 Digestive Disease Week
Algenpantucel-L Immunotherapy Phase 2 Data Featured in Plenary Session at 53rd Annual Meeting of the Society for Surgery of the Alimentary Tract and Will be Published in the Journal of Gastrointestinal Surgery
View HTML
Toggle Summary Data From Phase 1 and Phase 1B Studies of NewLink Genetics' IDO Pathway Inhibitor (NLG8189) Presented at 2012 ASCO Annual Meeting
NLG8189 Demonstrates Good Safety Profile and Bioavailability With Early Evidence of Activity
View HTML
Toggle Summary FDA Gives NewLink Genetics Approval to Proceed to Phase 1 Clinical Studies of Their Ebola Vaccine
  AMES, IA -- (Marketwired) -- 09/04/14 -- NewLink Genetics Corporation (NASDAQ: NLNK) today announced that the United States Food and Drug Administration (FDA) has given permission for the Company to proceed to Phase 1 clinical trials with their Ebola vaccine candidate.
View HTML